Background: Obstructive sleep apnea (OSA) increases the risk of dyslipidemia, thereby heightening the likelihood of developing cardiovascular diseases. Hence, prior to the diagnosis of OSA, it is essential to investigate the association with dyslipidemia in at-risk individuals. Methods: Using raw data obtained from the 2021 Korea National Health and Nutrition Examination Survey, we examined the details of 2,882 participants aged 40 years and older, who were not diagnosed with sleep apnea and did not use lipid-lowering medications. Participants who had reported snoring, fatigue, or witnessed apnea episodes, were categorized into the “OSA Risk Group” (OSARG), and logistic regression analysis was performed to examine the association between serum lipid levels and dyslipidemia. Results: OSARG participants were found to have a higher prevalence of hypertriglyceridemia and increased prevalence of dyslipidemia. After adjusting for sex, age, education, economic status, housing type, obesity, physical activity, smoking, and alcohol consumption, only hypertriglyceridemia remained significantly associated with the OSARG, and the odds ratio for OSA was significantly higher among those patients with hypertriglyceridemia (1.39; 95% confidence interval, 1.06–1.83). Conclusion Among adults aged 40 years and older, compared with those not at risk, individuals at risk of OSA were characterized by a higher prevalence of hypertriglyceridemia. These findings thus indicate that the management of hypertriglyceridemia and dyslipidemia may be warranted prior to the diagnosis of OSA in this population.

Background: Obstructive sleep apnea (OSA) increases the risk of dyslipidemia, thereby heightening the likelihood of developing cardiovascular diseases. Hence, prior to the diagnosis of OSA, it is essential to investigate the association with dyslipidemia in at-risk individuals. Methods: Using raw data obtained from the 2021 Korea National Health and Nutrition Examination Survey, we examined the details of 2,882 participants aged 40 years and older, who were not diagnosed with sleep apnea and did not use lipid-lowering medications. Participants who had reported snoring, fatigue, or witnessed apnea episodes, were categorized into the “OSA Risk Group” (OSARG), and logistic regression analysis was performed to examine the association between serum lipid levels and dyslipidemia. Results: OSARG participants were found to have a higher prevalence of hypertriglyceridemia and increased prevalence of dyslipidemia. After adjusting for sex, age, education, economic status, housing type, obesity, physical activity, smoking, and alcohol consumption, only hypertriglyceridemia remained significantly associated with the OSARG, and the odds ratio for OSA was significantly higher among those patients with hypertriglyceridemia (1.39; 95% confidence interval, 1.06–1.83). Conclusion Among adults aged 40 years and older, compared with those not at risk, individuals at risk of OSA were characterized by a higher prevalence of hypertriglyceridemia. These findings thus indicate that the management of hypertriglyceridemia and dyslipidemia may be warranted prior to the diagnosis of OSA in this population.

Background: Obstructive sleep apnea (OSA) increases the risk of dyslipidemia, thereby heightening the likelihood of developing cardiovascular diseases. Hence, prior to the diagnosis of OSA, it is essential to investigate the association with dyslipidemia in at-risk individuals. Methods: Using raw data obtained from the 2021 Korea National Health and Nutrition Examination Survey, we examined the details of 2,882 participants aged 40 years and older, who were not diagnosed with sleep apnea and did not use lipid-lowering medications. Participants who had reported snoring, fatigue, or witnessed apnea episodes, were categorized into the “OSA Risk Group” (OSARG), and logistic regression analysis was performed to examine the association between serum lipid levels and dyslipidemia. Results: OSARG participants were found to have a higher prevalence of hypertriglyceridemia and increased prevalence of dyslipidemia. After adjusting for sex, age, education, economic status, housing type, obesity, physical activity, smoking, and alcohol consumption, only hypertriglyceridemia remained significantly associated with the OSARG, and the odds ratio for OSA was significantly higher among those patients with hypertriglyceridemia (1.39; 95% confidence interval, 1.06–1.83). Conclusion Among adults aged 40 years and older, compared with those not at risk, individuals at risk of OSA were characterized by a higher prevalence of hypertriglyceridemia. These findings thus indicate that the management of hypertriglyceridemia and dyslipidemia may be warranted prior to the diagnosis of OSA in this population.

Background: Obstructive sleep apnea (OSA) increases the risk of dyslipidemia, thereby heightening the likelihood of developing cardiovascular diseases. Hence, prior to the diagnosis of OSA, it is essential to investigate the association with dyslipidemia in at-risk individuals. Methods: Using raw data obtained from the 2021 Korea National Health and Nutrition Examination Survey, we examined the details of 2,882 participants aged 40 years and older, who were not diagnosed with sleep apnea and did not use lipid-lowering medications. Participants who had reported snoring, fatigue, or witnessed apnea episodes, were categorized into the “OSA Risk Group” (OSARG), and logistic regression analysis was performed to examine the association between serum lipid levels and dyslipidemia. Results: OSARG participants were found to have a higher prevalence of hypertriglyceridemia and increased prevalence of dyslipidemia. After adjusting for sex, age, education, economic status, housing type, obesity, physical activity, smoking, and alcohol consumption, only hypertriglyceridemia remained significantly associated with the OSARG, and the odds ratio for OSA was significantly higher among those patients with hypertriglyceridemia (1.39; 95% confidence interval, 1.06–1.83). Conclusion Among adults aged 40 years and older, compared with those not at risk, individuals at risk of OSA were characterized by a higher prevalence of hypertriglyceridemia. These findings thus indicate that the management of hypertriglyceridemia and dyslipidemia may be warranted prior to the diagnosis of OSA in this population.

To construct a novel vaccine candidate against bovine enterotoxigenic Escherichia coli (ETEC), FanC, the major subunit of K99 fimbriae adhesion, was inserted into secretion plasmid pYA3560 containing a β-lactamase secretion system. This was then transformed into Δasd Δcrp Salmonella (S.) Typhimurium and designated as JOL950. Secretion of recombinant fanC fimbrial antigens was confirmed by immunoblot analysis. Groups of mice were inoculated with single or double doses of JOL950. Another group was used as a negative control. Compared to control mice, all immunized mice had significantly higher levels (p < 0.05) of serum immunoglobulin (Ig)G, and secretory IgA against FanC. The IgG2a and IgG1 titer assays revealed that immunization highly induced IgG2a compared to that of IgG1, indicating that T helper-1- related cell-mediated immune responses may be elicited by JOL950. The results show that both systemic and mucosal immunities against selected fimbrial antigens of bovine ETEC expressed by a live attenuated S. Typhimurium strain are prominently produced in mice immunized with JOL950 via an oral route.
Animals ; Enterotoxigenic Escherichia coli* ; Immunization ; Immunoglobulin A, Secretory ; Immunoglobulin G ; Immunoglobulins ; Mice* ; Plasmids ; Salmonella*

Integrase inhibitor is uniquely available as single tablet regimen (STR) in Korea. In this study, the durability until 96 weeks was compared between dolutegravir/abacavir/lamivudine (D/A/L) and elvitegravir/cobicistat/tenofovir/emtricitabine (E/T/E) in treatment naïve human immunodeficiency virus 1 (HIV-1) infected individuals. From 2014 to 2017, 153 and 234 subjects started D/A/L and E/T/E, respectively. During 96 weeks, 73 discontinued initial STR and the reason of discontinuation was typable in 44. The frequency of drug adverse event related discontinuation (AEDC) was higher in D/A/L (13.1% vs. 6.4%, P = 0.023) while most non-AE related discontinuations occurred in E/T/E (8/9), such as drug-drug interaction, meal requirement and virologic failure. AEDC occurred usually within 24 weeks (20/35) and D/A/L to E/T/E AEDC incidence rate ratio was 3.71 (95% confidence interval, 1.36–10.10) in this period. Regarding the durability, D/A/L and E/T/E revealed no significant difference at week 96 (P = 0.138) while durability of D/A/L was worse in the aspect of AEDC (P = 0.013).

In response to the Mpox domestic epidemic, South Korea initiated a nationwide vaccination program in May 2023, administering a 0.1 mL intradermal dose of JYNNEOS (Modified Vaccinia Ankara vaccine, Bavarian Nordic) to a high-risk group. To investigate the adverse reactions after intradermal JYNNEOS vaccination, an anonymous online survey was conducted at the National Medical Center from May 22 to July 31, 2023. Overall, 142 individuals responded. Over 80% of the respondents reported local reactions of predominantly mild severity. The predominant local reactions were pruritus, redness, and swelling; their incidence rates after the first dose were 66.2%, 48.1%, and 49.4%, respectively; the corresponding rates after the second dose were 69.2%, 60.6%, and 53.8%. Fewer respondents reported systemic symptoms. The most common systemic symptom was fatigue, the incidence rates of which after the first and second doses were 37.7% and 24.6%, respectively. Overall, the intradermally administered JYNNEOS vaccine appeared well tolerated.

The present study investigated prevalence of integrase strand transfer inhibitors (INSTI) resistance mutations in HIV-1-infected antiretroviral therapy (ART)-naïve patients in Korea. From 106 plasma samples, amplification and sequencing of integrase genes was performed, and major or minor mutations were calculated by the Stanford HIV drug resistance mutation interpretation algorithm. No major INSTI resistance mutations were found, and 14 minor mutations were detected in 13 (12.3%) patients. The present data support the recommendation that routine testing for INSTI resistance mutations before starting ART is not necessary.
Drug Resistance ; HIV ; Humans ; Integrases* ; Korea* ; Observational Study* ; Plasma ; Prevalence ; Prospective Studies*

Purpose: Panic disorder (PD) and PD with comorbid agoraphobia (PDA) share similar clinical characteristics but possess distinct symptom structures. However, studies specifically investigating the differences between PD and PDA are rare. Thus, the present study conducted a network analysis to examine the clinical networks of PD and PDA, focusing on panic symptom severity, anxiety sensitivity, anticipatory fear, and avoidance responses. By comparing the differences in network structures between PD and PDA, with the goal of identifying the central and bridge, we suggest clinical implications for the development of targeted interventions. Materials and Methods: A total sample (n=147; 55 male, 92 female) was collected from the psychiatric outpatient clinic of the university hospital. We conducted network analysis to examine crucial nodes in the PD and PDA networks and compared the two networks to investigate disparities and similarities in symptom structure. Results The most influential node within the PD network was Anxiety Sensitivity Index-Revised (ASI-R1; fear of respiratory symptom), whereas Panic Disorder Severity Scale (PDSS5; phobic avoidance of physical sensations) had the highest influence in the PDA network. Additionally, bridge centrality estimates indicated that each of the two nodes met the criteria for “bridge nodes” within their respective networks: ASI-R1 (fear of respiratory symptom) and Albany Panic and Phobic Questionnaire (APPQ3; interoceptive fear) for the PD group, and PDSS5 (phobic avoidance of physical sensation) and APPQ1 (panic frequency) for the PDA group Conclusion: Although the network comparison test did not reveal statistical differences between the two networks, disparities in community structure, as well as central and bridging symptoms, were observed, suggesting the possibility of distinct etiologies and treatment targets for each group. The clinical implications derived from the similarities and differences between PD and PDA networks are discussed.

Purpose: Panic disorder (PD) and PD with comorbid agoraphobia (PDA) share similar clinical characteristics but possess distinct symptom structures. However, studies specifically investigating the differences between PD and PDA are rare. Thus, the present study conducted a network analysis to examine the clinical networks of PD and PDA, focusing on panic symptom severity, anxiety sensitivity, anticipatory fear, and avoidance responses. By comparing the differences in network structures between PD and PDA, with the goal of identifying the central and bridge, we suggest clinical implications for the development of targeted interventions. Materials and Methods: A total sample (n=147; 55 male, 92 female) was collected from the psychiatric outpatient clinic of the university hospital. We conducted network analysis to examine crucial nodes in the PD and PDA networks and compared the two networks to investigate disparities and similarities in symptom structure. Results The most influential node within the PD network was Anxiety Sensitivity Index-Revised (ASI-R1; fear of respiratory symptom), whereas Panic Disorder Severity Scale (PDSS5; phobic avoidance of physical sensations) had the highest influence in the PDA network. Additionally, bridge centrality estimates indicated that each of the two nodes met the criteria for “bridge nodes” within their respective networks: ASI-R1 (fear of respiratory symptom) and Albany Panic and Phobic Questionnaire (APPQ3; interoceptive fear) for the PD group, and PDSS5 (phobic avoidance of physical sensation) and APPQ1 (panic frequency) for the PDA group Conclusion: Although the network comparison test did not reveal statistical differences between the two networks, disparities in community structure, as well as central and bridging symptoms, were observed, suggesting the possibility of distinct etiologies and treatment targets for each group. The clinical implications derived from the similarities and differences between PD and PDA networks are discussed.